U.S. Pain Foundation seeks to educate its members about all possible forms of treatment. Buprenorphine is one pain medication that has recently made headlines as a safer alternative to traditional opioid medications. Because it is a partial opioid agonist, it alleviates pain with less risk of euphoria and physical dependence as well as a smaller chance of respiratory depression.
U.S. Pain recently collaborated with The Herald Group to conduct an educational survey on members’ experiences with buprenorphine. More than 800 individuals responded. Here are some of the key findings from that survey:
U.S. Pain is asking its community to take a 22-question demographics survey. The survey takes about seven minutes to complete and covers types of pain condition, pain severity, treatment options, and more.
“We want to make sure we are effectively supporting and advocating for our pain warriors,” says Nicole Hemmenway, Interim CEO of U.S. Pain. “In order to do that, we need to understand their experiences.”